Cytokines are key mediators of immune responses that can modulate the antitumor activity
of immune cells. Cytokines have been explored as a promising cancer immunotherapy …

Polypharmacy is commonly employed in clinical settings. The potential risks of drug–drug
interactions (DDIs) can compromise efficacy and pose serious health hazards. Integrating …

Engineered T cells have emerged as highly effective treatments for hematological cancers.
Hundreds of clinical programs are underway in efforts to expand the efficacy, safety, and …

Introduction IL-15 agonists hold promise as immunotherapeutics due to their ability to induce
the proliferation and expansion of cytotoxic immune cells including natural killer (NK) and …

An insufficient quantity of functional T cells is a likely factor limiting the clinical activity of T-
cell bispecific antibodies, especially in solid tumor indications. We hypothesized that …

IL-15 has shown preclinical activity by enhancing the functional maturation of natural killer
(NK) cells. Clinical evaluation of the potential anticancer activity of most cytokines, including …

Introduction Interleukin 15 (IL-15) is a potential anticancer agent and numerous engineered
IL-15 agonists are currently under clinical investigation. Selective targeting of IL-15 to …

FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In
cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic …